Why the study?
Does NT-proBNP measurement improve prognostic risk stratification for mortality in patients with NSTE-ACS compared to TIMI risk score and ACC/AHA classification alone?
Does NT-proBNP measurement improve prognostic risk stratification for mortality in patients with NSTE-ACS compared to TIMI risk score and ACC/AHA classification alone?
NT-proBNP is a strong independent predictor of short- and medium-term mortality in NSTE-ACS, adding significant prognostic value beyond standard clinical risk scores.
Answers are grounded in this paper and cite their sources.
NT-proBNP may refine mortality risk stratification in NSTE-ACS; leaves open prospective validation against TIMI and ACC/AHA scores.
AIMS: We prospectively studied the additive value of N-terminal probrain natriuretic peptide (NT-proBNP) in relation to the Thrombolysis in Myocardial Infarction (TIMI) risk score and the American College of Cardiology/American Heart Association (ACC/AHA) joint prognostic classification, and compared the predictive capacity of NT-proBNP, troponin T (TnT), C-reactive protein (hsCRP), myoglobin, and creatine kinase-MB (CK-MB) concentrations in a cohort of 1483 consecutive patients with non-ST-segment-elevation acute coronary syndromes (NSTE-ACS). METHODS AND RESULTS: Centralised measurements of NT-proBNP, TnT, myoglobin, and hsCRP were performed 3 h (median) after admission. Adjusting by clinical, ECG variables, and biomarkers, NT-proBNP concentration was the strongest independent predictor of in-hospital (OR 1.7, 95% CI: 1.31-2.20, p < .001) and 180-day mortality (OR 1.67, 95% CI: 1.41-1.99, p < .001), and added significant prognostic information to the TIMI and ACC/AHA prognostic categories. NT-proBNP was not an independent predictor of risk of new myocardial infarction, even in the acute or long term. CONCLUSIONS: In NSTE-ACS, NT-proBNP adds substantial information to the TIMI risk score and the ACC/AHA classification. Compared to other biomarkers, NT-proBNP is the strongest independent predictor of in-hospital and 180-day mortality.
No takes yet. Share an insight, caveat, or question.
Óscar Bazzino (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: